Patents by Inventor Chad Daniel Hopkins

Chad Daniel Hopkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALTS AND FORMS OF A WEE1 INHIBITOR
    Publication number: 20230265097
    Abstract: The salt, such as adipate salt Form A, and freebase forms of Compound A are WEE inhibitors. Such salts and/or forms and freebase forms, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 24, 2023
    Inventors: Chad Daniel Hopkins, Peter Qinhua Huang, Kevin Duane Bunker
  • METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS
    Publication number: 20230234956
    Abstract: A process is provided for making a WEE1 inhibitor of the formula (1A) useful in the treatment of conditions characterized by excessive cellular proliferation, such as cancer. In some embodiments, processes are provided for making intermediate compounds of the formulae (3), (5) and (6) as defined herein.
    Type: Application
    Filed: June 9, 2021
    Publication date: July 27, 2023
    Inventors: Peter Qinhua Huang, Chad Daniel Hopkins, Brant Clayton Boren, Sunny Abraham, Kevin Duane Bunker, Sobhana Babu Boga, Shuguang Zhu, Tao Wu, Benjamin Pratt
  • PREPARATION OF AN SELECTIVE ESTROGEN RECEPTOR DEGRADER
    Publication number: 20230212118
    Abstract: Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.
    Type: Application
    Filed: April 21, 2021
    Publication date: July 6, 2023
    Inventors: Peter Qinhua Huang, Sayee Gajanan Hegde, Kevin Duane Bunker, John Knight, Joseph Robert Pinchman, Aditya Krishnan Unni, Rakesh Kumar Sit, Shuguang Zhu, Chad Daniel Hopkins, Ian Scott
  • Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones
    Patent number: 11261192
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: March 1, 2022
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
  • Analgesic compounds
    Patent number: 11242327
    Abstract: Disclosed herein are compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), and methods of using compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It) as an analgesic.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: February 8, 2022
    Assignee: Recurium IP Holdings, LLC
    Inventors: Chad Daniel Hopkins, Joseph Robert Pinchman, Kevin Duane Bunker, Deborah Helen Slee, Brant Clayton Boren, Mehmet Kahraman
  • SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES
    Publication number: 20220024939
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: October 8, 2021
    Publication date: January 27, 2022
    Inventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
  • EGFR INHIBITOR COMPOUNDS
    Publication number: 20210395230
    Abstract: Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 23, 2021
    Applicant: Recurium IP Holdings, LLC
    Inventors: Kevin Duane Bunker, Peter Qinhua Huang, Sunny Abraham, Joseph Robert Pinchman, Chad Daniel Hopkins, Deborah Helen Slee
  • ESTROGEN RECEPTOR MODULATORS
    Publication number: 20210330651
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: July 6, 2021
    Publication date: October 28, 2021
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • EGFR inhibitor compounds
    Patent number: 11098030
    Abstract: Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 24, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Kevin Duane Bunker, Peter Qinhua Huang, Sunny Abraham, Joseph Robert Pinchman, Chad Daniel Hopkins, Deborah Helen Slee
  • Estrogen receptor modulators
    Patent number: 11065234
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: July 20, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • Estrogen receptor modulators
    Patent number: 11065233
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: July 20, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES
    Publication number: 20210139482
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: February 26, 2019
    Publication date: May 13, 2021
    Inventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
  • Bicyclic compounds
    Patent number: 10975035
    Abstract: Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: April 13, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Kevin Duane Bunker, Chuangxing Guo, Mark Charles Grier, Chad Daniel Hopkins, Joseph Robert Pinchman, Deborah Helen Slee, Peter Qinhua Huang, Mehmet Kahraman
  • ACRYLIC ACID ANALOGS
    Publication number: 20210094899
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: July 26, 2018
    Publication date: April 1, 2021
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Kevin Duane Bunker, Sayee Gajanan Hegde, Chad Daniel Hopkins
  • Estrogen receptor modulators
    Patent number: 10959989
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: March 30, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • Methods for cross coupling
    Patent number: 10793504
    Abstract: Methods of preparing substituted bicyclo[0.1.1.1]pentane compounds of Formula (I) comprise reacting a compound of Formula (A) with a compound of Formula (B) in the presence of a first transition metal catalyst selected from a palladium catalyst and a nickel catalyst, where the variables R1, R2, X1 and X2 are as described herein.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 6, 2020
    Assignee: Recurium IP Holdings, LLC
    Inventors: Joseph Robert Pinchman, Chad Daniel Hopkins, Kevin Duane Bunker, Peter Qinhua Huang
  • ANALGESIC COMPOUNDS
    Publication number: 20200270221
    Abstract: Disclosed herein are compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), and methods of using compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It) as an analgesic.
    Type: Application
    Filed: May 11, 2018
    Publication date: August 27, 2020
    Inventors: Chad Daniel Hopkins, Joseph Robert Pinchman, Kevin Duane Bunker, Deborah Helen Slee, Brant Clayton Boren, Mehmet Kahraman
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20200268714
    Abstract: Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
    Type: Application
    Filed: January 6, 2020
    Publication date: August 27, 2020
    Inventors: Peter Qinhua Huang, Mehmet Kahraman, Deborah Helen Slee, Kevin Duane Bunker, Chad Daniel Hopkins, Joseph Robert Pinchman, Sunny Abraham, Rakesh Kumar Sit, Daniel Lee Severance
  • ESTROGEN RECEPTOR MODULATORS
    Publication number: 20200261429
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: May 5, 2020
    Publication date: August 20, 2020
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • ESTROGEN RECEPTOR MODULATORS
    Publication number: 20200261428
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: May 5, 2020
    Publication date: August 20, 2020
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit